Taken together, these findings indicate that aberrant overexpression of MUC4 in pancreatic cancer contributes resistance to chemotherapeutic agent gemcitabine by activation of MUC4-HER2-mediated anti-apoptotic pathway. This evidence concerns the gene ERBB2 and familial pancreatic carcinoma.